Detalles de la búsqueda
1.
Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants.
Br J Clin Pharmacol
; 89(7): 2208-2215, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36808638
2.
The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.
Invest New Drugs
; 38(1): 131-139, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31728714
3.
The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Eur J Clin Pharmacol
; 71(12): 1441-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26381275
4.
Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects.
Xenobiotica
; 45(1): 45-59, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25034009
5.
Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Eur J Drug Metab Pharmacokinet
; 49(3): 367-381, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38554232
6.
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
Clin Pharmacokinet
; 63(2): 171-182, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38079095
7.
No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
Antimicrob Agents Chemother
; 56(5): 2408-13, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22371898
8.
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Cancer Chemother Pharmacol
; 89(1): 71-81, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34698901
9.
Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants.
Clin Pharmacol Drug Dev
; 11(1): 34-42, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34825782
10.
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Eur J Drug Metab Pharmacokinet
; 47(3): 419-429, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35226304
11.
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
J Clin Pharmacol
; 61(10): 1311-1323, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33749838
12.
Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Clin Pharmacol Drug Dev
; 10(11): 1395-1404, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34288547
13.
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
Clin Pharmacokinet
; 60(10): 1313-1324, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33937954
14.
Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function.
Cancer Chemother Pharmacol
; 86(6): 701-710, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33037918
15.
The Bioequivalence of Tafamidis 61-mg Free Acid Capsules and Tafamidis Meglumine 4 × 20-mg Capsules in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 9(7): 849-854, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32196976
16.
Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.
Cancer Chemother Pharmacol
; 81(4): 659-670, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29468455
17.
Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
J Clin Pharmacol
; 47(11): 1421-9, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17962429
18.
Effect of food on the bioavailability of palbociclib.
Cancer Chemother Pharmacol
; 79(3): 527-533, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28204912
19.
Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Cancer Chemother Pharmacol
; 89(6): 839, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35303141
20.
Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
Clin Pharmacol Drug Dev
; 6(6): 614-626, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28430398